Boston Scientific Corporation ($BSX) Stock Forecast: Down 5.2% Today

What is Boston Scientific Corporation?

Boston Scientific (BSX) is a leading medical technology company that specializes in developing innovative medical solutions, particularly in the areas of cardiovascular, urology, and endoscopy. The company has been a market leader in its niche and has maintained a strong position in the industry.

Why is Boston Scientific Corporation going down?

BSX stock is down 5.2% on May 28, 2026 13:56

• Boston Scientific (BSX) stock plunged by 12.53% today due to the company reiterating underwhelming full-year organic growth guidance and citing softer demand in its WATCHMAN and urology franchises.
• Despite trading at 15 times forward earnings and maintaining market leadership, analysts believe the lower end of its sales guidance is more realistic, especially with expected flat sequential sales growth for the WATCHMAN device.
• The disappointing market movement reflects investors' concerns about the company's growth prospects and the impact of softer demand on its key product lines, leading to a significant sell-off in the stock.
• This highlights the importance of managing market expectations and delivering positive outlooks to maintain investor confidence and avoid sharp declines in stock value.

BSX Price Chart

BSX Technical Analysis

BSX News

Guardant Health Stock Rockets 34% With 7-Day Winning Streak

Guardant Health (GH) stock has experienced a 34% surge over a 7-day winning streak, increasing its market cap by $4.3 billion to $17 billion. Despite this strong performance and a robust financial condition, Trefis analysts flag the stock as "Relatively Expensive" due to its "Very High valuation." The article emphasizes the importance of predictive signals over notifications for identifying future winning stocks, suggesting that current gains are already priced into the market.

https://www.trefis.com/articles/600581/guardant-health-stock-rockets-34-with-7-day-winning-streak/2026-05-28

Allstate Corp Acquires 12,613 Shares of Marathon Petroleum Corporation $MPC

Allstate Corp significantly increased its stake in Marathon Petroleum (NYSE:MPC) by 117.6% in the fourth quarter, now holding 23,334 shares valued at approximately $3.8 million. This acquisition comes as Marathon Petroleum shows strong financial performance, beating earnings estimates with an EPS of $1.65 and revenue of $34.2 billion, and maintaining a "Moderate Buy" consensus rating from analysts with an average price target of $268.50. The company also declared a quarterly dividend of $1.00 per share.

https://www.marketbeat.com/instant-alerts/filing-allstate-corp-acquires-12613-shares-of-marathon-petroleum-corporation-mpc-2026-05-28/

Abbott Clears AI Cardiology And Dual Sensors As Shares Face Pressure

Abbott Laboratories (NYSE:ABT) has secured US and European clearances for its Ultreon 3.0 AI-powered coronary imaging platform and the Libre Duo dual continuous glucose-ketone sensor, alongside reaffirmation of its noninvasive colorectal cancer screening solutions. These regulatory successes come as Abbott's stock has faced significant pressure, with shares down over 30% year-to-date and over the past year. The company will also present new cancer diagnostics evidence at the ASCO Annual Meeting, highlighting its focus on expanding its medical technology and diagnostics portfolio amidst a challenging stock performance.

https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-clears-ai-cardiology-and-dual-sensors-as-shares-face

How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) Glioblastoma Trial Enrolment Milestone

Telix Pharmaceuticals completed enrolment for its Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma, observing no dose-limiting toxicities. This development supports its strategy to build a neuro-oncology franchise with LAT1-targeted theranostics. Investors are evaluating this scientific progress against the backdrop of significant R&D investment and anticipated future revenues, with some analysts projecting a substantial upside.

https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-investors-are-reacting-to-telix-pharmaceuticals-asxtlx-g

Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance

Boston Scientific (NYSE:BSX) experienced a 12.53% stock drop today after reiterating its underwhelming full-year organic growth guidance and noting softer demand in its WATCHMAN and urology franchises. Despite its stock being halved, trading at 15 times forward earnings, and maintaining market leadership in its niche, analysts believe the lower end of its sales guidance is more realistic due to expected flat sequential sales growth for the WATCHMAN device. This comes as investors had hoped for a more positive outlook from the company's conference presentation.

https://finance.yahoo.com/markets/stocks/articles/stock-market-today-may-27-213111534.html

Trending Today

Chipotle Mexican Grill Inc. ($CMG) Stock Forecast: Down 5.0% Today

CME Group Inc. ($CME) Stock Forecast: Down 5.4% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Up 5.3% Today

Teleflex Incorporated ($TFX) Stock Forecast: Up 2.1% Today

Xerox Corporation ($XRX) Stock Forecast: Down 7.6% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 9.6% Today

Gartner Inc. ($IT) Stock Forecast: Up 5.8% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.3% Today

BlackLine, Inc. ($BL) Stock Forecast: Up 5.2% Today

Equifax Inc. ($EFX) Stock Forecast: Up 5.1% Today

Boston Scientific Corporation Price History

27.04.2026 - BSX Stock was down 12.0%

• Boston Scientific's stock saw a notable decline of around 10% to a 52-week low subsequent to the announcement of reduced demand for its WATCHMAN cardiac implant.
• The decrease in stock value was amplified by Boston Scientific's choice to revise its full-year organic growth outlook due to challenges in the standalone WATCHMAN growth, decreased Electrophysiology guidance, and weaker performance in the urology segment.
• Investor confidence was further impacted by new product launches by Boston Scientific's competitors in the Electrophysiology field, intensifying the company's existing challenges.
• The combination of factors, including the revised guidance and increased market competition, led to a significant drop in Boston Scientific's stock value, reflecting concerns regarding the company's future growth and competitiveness.

21.03.2026 - BSX Stock was down 5.1%

• Boston Scientific Corp. (BSX) saw a bearish market movement today.
• A decision to lower the price target for BSX, based on electrophysiology hospital-purchasing data and mixed reactions to recent trial results, may have influenced the negative market sentiment.
• Concerns about a slightly higher ischemic stroke rate in the trial results could have impacted investor confidence, despite some analysts maintaining positive outlooks on the company.
• Market reaction to uncertainties about BSX's electrophysiology segment performance and the trial results' potential impact on revenue projections likely led to the observed bearish trend today.

24.03.2026 - BSX Stock was down 5.3%

• BSX stock had a bearish movement today, possibly influenced by the comparison trial announcement between Johnson & Johnson's Varipulse Pro PFA platform and Boston Scientific's Farapulse system. Concerns about competition and market share might have impacted investor sentiment.
• Despite the bearish movement, BSX has recently shown strong performance compared to peers and the broader market, indicating resilience and growth potential. This decline could be a temporary setback rather than a long-term trend.
• Analysts maintain a Buy rating on Boston Scientific, emphasizing significant upside potential, suggesting the company's solid fundamentals. Investors may view the current dip as a buying opportunity in anticipation of future growth.

24.03.2026 - BSX Stock was down 5.3%

• Boston Scientific Corp. experienced a notable downward trend in its stock price today, despite receiving positive updates and showing resilience in the market.
• Concerns arose as Johnson & Johnson initiated a direct comparison clinical trial between Varipulse and Boston Scientific's Farapulse for treating atrial fibrillation, potentially impacting market competition and share.
• While the company saw a strong start and reported impressive quarterly net sales, the decline in stock value could be linked to investors taking profits following recent growth.
• The overall market's negative performance today likely also weighed on BSX shares, despite the company's recent market outperformance.

27.04.2026 - BSX Stock was down 10.5%

• The decline in BSX stock could be a result of investors taking profits after a period of strong growth subsequent to a robust Q1 performance and increased guidance.
• Recent positive developments in Johnson & Johnson's IVL technology, specifically the launch of the Shockwave C2 Aero catheter, might have briefly diverted attention from Boston Scientific within the investment community.
• Although BSX remains a significant player in the medical devices sector, today's market sentiment could have been influenced by the spotlight on other companies such as Johnson & Johnson and IDEXX Laboratories, Inc., which were hailed as top medical technology stocks for acquisition.
• Investors may be reassessing their BSX holdings amidst the competitive environment and ongoing technological advancements in the medical technology sector, contributing to the observed bearish movement.

27.04.2026 - BSX Stock was down 9.8%

• Boston Scientific's stock experienced a significant bearish movement, dropping by approximately 10% to a 52-week low, following the announcement of a slowdown in demand for its WATCHMAN cardiac implant.
• The company's decision to lower its full-year organic growth guidance due to challenges in standalone WATCHMAN growth, competitor launches in the Electrophysiology segment, and softness in the urology segment contributed to the negative market sentiment.
• Despite the setbacks, management remains optimistic about achieving margin improvement and double-digit EPS growth, with plans to provide further updates on its long-range plan.
• Boston Scientific's strategic investment in MiRus, aiming to acquire the Transcatheter Aortic Valve Replacement (TAVR) business, reflects the company's commitment to future technology acquisitions and innovation in the MedTech sector amidst evolving market dynamics.

28.04.2026 - BSX Stock was down 5.2%

• Boston Scientific (BSX) stock plunged by 12.53% today due to the company reiterating underwhelming full-year organic growth guidance and citing softer demand in its WATCHMAN and urology franchises.
• Despite trading at 15 times forward earnings and maintaining market leadership, analysts believe the lower end of its sales guidance is more realistic, especially with expected flat sequential sales growth for the WATCHMAN device.
• The disappointing market movement reflects investors' concerns about the company's growth prospects and the impact of softer demand on its key product lines, leading to a significant sell-off in the stock.
• This highlights the importance of managing market expectations and delivering positive outlooks to maintain investor confidence and avoid sharp declines in stock value.

22.03.2026 - BSX Stock was up 5.7%

• Boston Scientific is a leading medical technology company focused on developing innovative solutions to transform patient lives.
• The stock of Boston Scientific (BSX) experienced a strong bullish movement today.
• The positive market reaction can be attributed to the company's robust first-quarter 2026 results, including significant revenue growth and exceeding earnings expectations.
• Key factors contributing to the bullish sentiment could be the successful clinical trial outcomes, regulatory approvals, and strategic acquisitions announced by Boston Scientific.
• Investors likely responded favorably to the company's updated full-year guidance, reflecting confidence in its growth trajectory and market positioning.

22.03.2026 - BSX Stock was up 7.2%

• Boston Scientific is a leading medical technology company focusing on innovative solutions to enhance patient care. The company has a history of positive clinical trial outcomes and meeting regulatory milestones.
• Net sales for Boston Scientific saw an 11.6% increase in the first quarter of 2026. The company surpassed its earnings per share (EPS) expectations, reflecting strong financial performance.
• Positive results from clinical trials of key medical devices like the WATCHMAN FLX™ and EKOS™ systems have boosted investor confidence in the company's growth trajectory.
• The market reacted favorably to Boston Scientific's optimistic guidance for the full year and second quarter of 2026, signaling expected sales growth and a positive outlook.
• Boston Scientific's robust financial performance and promising future outlook likely drove investor confidence and contributed to the bullish movement in its stock price.

22.03.2026 - BSX Stock was up 5.8%

• Boston Scientific reported impressive first-quarter 2026 results, surpassing expectations with significant revenue growth and positive clinical trial outcomes for key medical devices.
• Despite the positive financial performance, the stock initially experienced a decline, potentially due to broader sector pressure or market participants expecting a normalization in growth after the strong results.
• The appointment of Aamir Paul as the new CEO of Regal Rexnord, a move from Schneider Electric, might have also influenced market sentiment positively, reflecting leadership changes in related industries.
• Overall, Boston Scientific's robust performance and strategic advancements in its product portfolio and regulatory approvals likely contributed to the bullish movement in its stock price today.

22.03.2026 - BSX Stock was up 8.5%

• Despite adjustments to its 2026 guidance related to challenges in its electrophysiology, Watchman, and urology segments, Boston Scientific's stock witnessed a significant bullish movement.
• Market response was likely influenced by the company's strong performance in the first quarter of 2026, marked by substantial revenue growth and positive future outlook.
• Investors may interpret the revised guidance as a proactive measure to tackle present difficulties and position the company for growth, leading to optimistic sentiment towards the stock.
• The market appears to be focusing on Boston Scientific's strategic initiatives and long-term prospects, driving up the stock's value despite the revised projections.

08.04.2026 - BSX Stock was down 5.0%

• The stock of Boston Scientific Corp. (BSX) experienced a strong bearish movement today, hitting a new 52-week low of $55.94.
• The bearish trend can be attributed to a combination of factors:
• Analyst downgrades despite a modest quarterly beat may have raised concerns among investors about near-term growth and profitability.
• The FDA's classification of a recall of Boston Scientific's Accolade pacemakers as the most serious type due to reported deaths and injuries likely added to investor uncertainty.
• Despite the recent downturn, analysts still maintain a "Moderate Buy" rating on BSX with an average price target of $93.91, citing strong fundamentals amidst market volatility and competitive pressures.
• The overall market sentiment for BSX remains mixed, with institutional investors like Glenview Trust Co increasing their holdings, while analysts issue positive ratings but acknowledge challenges ahead.